Institute for Preventive Medicine of China Medical University, Shenyang, China.
Institute for AIDS/STD Control and Prevention, Liaoning Provincial Center for Disease Prevention and Control, Shenyang, China.
AIDS Res Hum Retroviruses. 2022 Jun;38(6):502-509. doi: 10.1089/AID.2021.0079. Epub 2022 Apr 25.
This study aimed to monitor the prevalence of HIV-1 drug resistance and risk factors associated with drug resistance in antiretroviral therapy (ART)-failure individuals in Liaoning Province, China. Plasma samples were collected from HIV-1-positive individuals who experienced ART failure in Liaoning Province between April 2018 and September 2019. Genotype resistance test was performed using an in-house assay on these collected samples. Factors associated with drug resistance were identified by logistic regression analysis. We collected a total of 468 ART-failure individuals, of which 256 were successfully included in the final study. Of these, the most predominant genotype was CRF01_AE, accounting for 77.73%. The resistance rate to any of the three classes of antiretroviral drugs (non-nucleoside reverse transcriptase inhibitors [NNRTIs], nucleoside reverse transcriptase inhibitors [NRTIs], and protease inhibitors [PIs]) was 64.84%. Among 256 ART-failure patients, 62.89% showed drug resistance to NNRTIs, 50.39% to NRTIs, and 3.13% to PIs. G190S (31.25%) and Y181C (25.78%) mutations were the most common NNRTIs resistance mutations. K65R (29.69%), M184V (28.52%) were the most common NRTIs resistance mutations. Factors associated with drug resistance included current ART regimen and viral load. The high drug resistance rate among ART-failure individuals in Liaoning Province needs more attention. Corresponding strategies for the risk factors associated with HIV drug resistance can better control and prevent the prevalence of resistance.
本研究旨在监测中国辽宁省接受抗逆转录病毒治疗（ART）失败的个体中 HIV-1 耐药的流行情况和与耐药相关的危险因素。从 2018 年 4 月至 2019 年 9 月期间在中国辽宁省经历 ART 失败的 HIV-1 阳性个体中采集血浆样本。使用内部测定法对这些采集的样本进行基因型耐药性检测。通过逻辑回归分析确定与耐药相关的因素。我们共收集了 468 名 ART 失败的个体，其中 256 名成功纳入最终研究。其中，最主要的基因型是 CRF01_AE，占 77.73%。对任何三类抗逆转录病毒药物（非核苷类逆转录酶抑制剂[NNRTIs]、核苷类逆转录酶抑制剂[NRTIs]和蛋白酶抑制剂[PIs]）的耐药率为 64.84%。在 256 名 ART 失败患者中，62.89%对 NNRTIs 耐药，50.39%对 NRTIs 耐药，3.13%对 PIs 耐药。G190S（31.25%）和 Y181C（25.78%）突变是最常见的 NNRTIs 耐药突变。K65R（29.69%）和 M184V（28.52%）是最常见的 NRTIs 耐药突变。与耐药相关的因素包括当前的 ART 方案和病毒载量。辽宁省 ART 失败个体中耐药率较高，需要引起更多关注。针对与 HIV 耐药相关的危险因素制定相应的策略，可以更好地控制和预防耐药的发生。
